Salinomycin Effectively Eliminates Cancer Stem-Like Cells and Obviates Hepatic Metastasis in Uveal Melanoma

2019 ◽  
Author(s):  
Jingfeng Zhou ◽  
Shenglan Liu ◽  
Yun Wang ◽  
Wei Dai ◽  
Shubo Wang ◽  
...  
Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3359
Author(s):  
Elias Koch ◽  
Anne Petzold ◽  
Anja Wessely ◽  
Edgar Dippel ◽  
Anja Gesierich ◽  
...  

Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only.


2017 ◽  
Vol 15 (1) ◽  
Author(s):  
Ken Kageyama ◽  
Masahiro Ohara ◽  
Kengo Saito ◽  
Shinji Ozaki ◽  
Mizue Terai ◽  
...  

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 9535-9535
Author(s):  
Carin F. Gonsalves ◽  
David J. Eschelman ◽  
Robert D. Adamo ◽  
P. Rani Anne ◽  
Marlana M. Orloff ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 405 ◽  
Author(s):  
Terai ◽  
Londin ◽  
Rochani ◽  
Link ◽  
Lam ◽  
...  

Uveal melanoma (UM) is the most common primary eye malignancy in adults and up to 50% of patients subsequently develop systemic metastasis. Metastatic uveal melanoma (MUM) is highly resistant to immunotherapy. One of the mechanisms for resistance would be the immune-suppressive tumor microenvironment. Here, we have investigated the role of tryptophan 2,3-dioxygenase (TDO) in UM. Both TDO and indoleamine 2,3-dioxygenase (IDO) catalyze tryptophan and produce kynurenine, which could cause inhibition of T cell immune responses. We first studied the expression of TDO on tumor tissue specimens obtained from UM hepatic metastasis. High expression of TDO protein was confirmed in all hepatic metastasis. TDO was positive in both normal hepatocytes and the tumor cells with relatively higher expression in tumor cells. On the other hand, IDO protein remained undetectable in all of the MUM specimens. UM cell lines established from metastasis also expressed TDO protein and increasing kynurenine levels were detected in the supernatant of MUM cell culture. In TCGA database, higher TDO2 expression in primary UM significantly correlated to BAP1 mutation and monosomy 3. These results indicate that TDO might be one of the key mechanisms for resistance to immunotherapy in UM.


2007 ◽  
Vol 48 (10) ◽  
pp. 4399 ◽  
Author(s):  
Vivian Barak ◽  
Shahar Frenkel ◽  
Klara Valyi-Nagy ◽  
Lu Leach ◽  
Marsha A. Apushkin ◽  
...  

2013 ◽  
Author(s):  
Shinji Ozaki ◽  
Makoto Yoshida ◽  
Mizue Terai ◽  
Senthamil Selvan ◽  
Michael J. Mastrangelo ◽  
...  

1985 ◽  
Vol 100 (5) ◽  
pp. 666-668 ◽  
Author(s):  
Jerry A. Shields ◽  
James J. Augsburger ◽  
Larry A. Donoso ◽  
Vitaliano B. Bernardino ◽  
Myron Portenar

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Jingfeng Zhou ◽  
Shenglan Liu ◽  
Yun Wang ◽  
Wei Dai ◽  
Hailin Zou ◽  
...  

An amendment to this paper has been published and can be accessed via the original article.


Sign in / Sign up

Export Citation Format

Share Document